Drug Trial Radar · NCT06826313
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 19, 2025
Primary completion
Dec 30, 2028
Study completion Mar 1, 2029
Sponsor
- Lead sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Third Affiliated Hospital, Sun Yat-Sen University
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Conditions
- Solid Tumors
Interventions
VRT106Biological
Intravenous drip administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with advanced malignanttumorsTime frame: About 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.